Journal
SEMINARS IN IMMUNOLOGY
Volume 48, Issue -, Pages -Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.smim.2020.101406
Keywords
Tertiary lymphoid structures; B cells; Adaptive anti-tumor response; Prognosis; Clinical outcome; Immunotherapy
Categories
Funding
- INSERM
- Sorbonne Universite
- Universite de Paris
- CARPEM (Cancer Research for Personnalized Medecine) programme of the Sites Integres de Recherche sur le Cancer (SIRIC)
- LabeX Immunooncology
- Foncer contre le Cancer
Ask authors/readers for more resources
Tumors progression is under the control of a heterogeneous microenvironment composed of immune cells, fibroblasts, blood and lymphatic vessels, in which T cells have been demonstrated to be major actors, through their cytotoxic and cytokine producing effector functions and their long term memory that protects against metastasis. In this scenario, lessons from mouse models taught that B cells exert a protumoral role, via macrophage-dependent activation of inflammation. However, it became progressively evident from studies in patients with human cancers that the anti-tumor responses can be generated and controlled in tertiary lymphoid structures (TLS) that concentrate most of the intratumoral B cells and where B cells can differentiate into plasma cells and memory cells. Furthermore, recent studies demonstrated that the presence in tumors of B cells and TLS are associated with favorable outcome in patients treated by immunotherapy, unraveling TLS as a new predictive marker of anti-tumor response human cancers. This review encompasses the characteristics and functions of TLS and of B cells in human tumors, their prognostic and theranostic impact and summarizes the mouse models used to induce TLS neogenesis in tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available